Cerus Corporation has unveiled its preliminary financial performance for 2024, highlighting impressive growth in product revenue. According to the company's official statement, they recorded a full-year product revenue of $180.3 million, which marks a 15% increase compared to the previous year. Notably, their INTERCEPT Fibrinogen Complex (IFC) revenue soared to $9.2 million, a 42% rise from 2023, as cited by ir.cerus.com.
Looking ahead, Cerus has provided revenue guidance for 2025, forecasting product revenues between $194 million and $200 million, representing an 8% to 11% increase year-over-year. For IFC, they anticipate revenues to range from $12 million to $15 million. Strategies moving into 2025 include the introduction of their LED Illuminator in Europe, a move aimed at broadening their market reach and product line.
In addition to these financial developments, Cerus Corporation has successfully maintained positive operating cash flows for the fourth consecutive quarter, showcasing robust financial health and solid operational capabilities, as noted by Nasdaq.com. This strong financial performance is coupled with strategic initiatives that underline the company's commitment to advancing growth and innovation in the blood safety industry.